Morpholinopurine derivatives
AssigneeDaiichi Sankyo Company, Limited
InventorsKiyoshi Nakayama, Kazuyuki Sugita, Masaki Setoguchi, Yuichi Tominaga, Masanori Saitou, Takashi Odagiri
Life of this patent
Estimating the term…
Abstract
There is provided a novel compound that inhibits phosphatidylinositol 3-kinase (PI3K) and/or the mammalian target of rapamycin (mTOR) and exhibits anti-tumor activity. The present invention provides a compound represented by the following formula (1) having various substituents that inhibits PI3K and/or mTOR and exhibits anti-tumor activity: wherein R1, R2, R3, R4, Ra, Rb, Rc, and X each have the same meaning as defined in the specification.
Claims13
A medicament comprising of a compound represented by the formula:
- or a pharmaceutically acceptable salt thereof as an active ingredient.
A pharmaceutical composition comprising a compound represented by the formula:
- or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
A method for inhibiting phosphatidylinositol 3-kinase (PI3K) in a subject, comprising administering to a subject in need thereof an effective amount of a compound represented by the formula:
- or a pharmaceutically acceptable salt thereof.
A method for inhibiting the mammalian target of rapamycin (mTOR) in a subject, comprising administering to a subject in need thereof an effective amount of a compound represented by the formula:
- or a pharmaceutically acceptable salt thereof.
A method for inhibiting phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) in a subject, comprising administering to a subject in need thereof an effective amount of a compound represented by the formula:
- or a pharmaceutically acceptable salt thereof.
A method for treating a tumor, comprising administering to a subject in need thereof an effective amount of a compound represented by the formula:
- or a pharmaceutically acceptable salt thereof, wherein the tumor is selected from the following group:
- ovary cancer, colon cancer, and endometrial cancer.
Dependencies are inferred from the claim text.